Our case report confirms the therapeutic effectiveness of using ICIs in conjunction with antiangiogenic drugs to treat this PD-L1-positive and vascular-rich advanced rare tumor, providing evidence to support the clinical treatment of SCC. The gene discussed is CD274; the disease is neoplasm.